Angélique Bastienne van ‘t Wout
Research Subjects
Research Interests
Angélique Bastienne van ‘t Wout has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
Hanneke Schuitemaker
Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory and Center for Infectious Diseases and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
8 shared publications- Hanneke Schuitemaker
Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
5 shared publications - Neeltje A. Kootstra
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, The Netherlands
5 shared publications - Rosita Bihariesingh-Sanchit
Department of Anesthesiology, Academic Hospital Paramaribo
4 shared publications Agnes M. Harskamp
Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory and Center for Infectious Diseases and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3 shared publicationsDaniëlle van Manen
Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infectious Diseases and Immunity Amsterdam at the Academic Medical Center of the University of Amsterdam, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1301
Feasibility and outcomes of crossflow membrane plasmapheresis for long COVID in Suriname: a randomized double-blind placebo-controlled pilot trial
Background Long COVID is heterogeneous and currently without cure. The disease resembles myalgic encephalomyelitis/chronic fatigue syndrome, which is driven by autoantibodies, leading to exploration of therapeutic plasma exchange (TPE) to reduce autoantibody levels as a potential treatment option. Methods We conducted a randomized, double-blind, placebo-controlled clinical trial comparing TPE with placebo treatment in a resource-limited setting in Suriname. Participants were adults aged 18 to 65 years with physician-confirmed long COVID and questionnaire-defined functional impairment. Treatment consisted of 5 TPE or placebo treatment (blood draw followed by whole blood reinfusion) sessions each separated by two days. Clinical outcomes were assessed using three different fatigue scores at baseline, day 28 and day 90. Results Of 189 patients assessed for eligibility, 18 were randomized and analyzed (mean age [SD], 46 years; 11 females [61%]; mean baseline Chalder fatigue score, 21). While Chalder fatigue scores at 90 days were significantly improved over baseline in the TPE group (mean [SD] at baseline: 20, 90 days: 10, P = 0.0003) and not in the placebo group (baseline: 22, 90 days: 12, P = 0.0628), between both groups the scores were not statistically significantly different at 90 days ( P = 0.8770). There was also no significant difference in the percentage of patients that achieved >30% Chalder fatigue score improvement (9 of 11 TPE-treated patients (81.8%) versus 5 of 7 placebo-treated patients (71.4%); difference 10.4% [95% CI, -33.4% to 51.8%]; P > .9999). Results were consistent among the three different fatigue scores used. No serious treatment-emergent adverse events were reported in either group. Conclusions Our study found reductions in fatigue in both the TPE- and placebo-treatment groups. Larger randomized trials with biomarker-guided patient selection may be required to demonstrate a beneficial effect of TPE in long COVID.
- 5 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1301
Open AccessFeasibility and outcomes of crossflow membrane plasmapheresis for long COVID in Suriname: a randomized double-blind placebo-controlled pilot trial
Background Long COVID is heterogeneous and currently without cure. The disease resembles myalgic encephalomyelitis/chronic fatigue syndrome, which is driven by autoantibodies, leading to exploration of therapeutic plasma exchange (TPE) to reduce autoantibody levels as a potential treatment option. Methods We conducted a randomized, double-blind, placebo-controlled clinical trial comparing TPE with placebo treatment in a resource-limited setting in Suriname. Participants were adults aged 18 to 65 years with physician-confirmed long COVID and questionnaire-defined functional impairment. Treatment consisted of 5 TPE or placebo treatment (blood draw followed by whole blood reinfusion) sessions each separated by two days. Clinical outcomes were assessed using three different fatigue scores at baseline, day 28 and day 90. Results Of 189 patients assessed for eligibility, 18 were randomized and analyzed (mean age [SD], 46 years; 11 females [61%]; mean baseline Chalder fatigue score, 21). While Chalder fatigue scores at 90 days were significantly improved over baseline in the TPE group (mean [SD] at baseline: 20, 90 days: 10, P = 0.0003) and not in the placebo group (baseline: 22, 90 days: 12, P = 0.0628), between both groups the scores were not statistically significantly different at 90 days ( P = 0.8770). There was also no significant difference in the percentage of patients that achieved >30% Chalder fatigue score improvement (9 of 11 TPE-treated patients (81.8%) versus 5 of 7 placebo-treated patients (71.4%); difference 10.4% [95% CI, -33.4% to 51.8%]; P > .9999). Results were consistent among the three different fatigue scores used. No serious treatment-emergent adverse events were reported in either group. Conclusions Our study found reductions in fatigue in both the TPE- and placebo-treatment groups. Larger randomized trials with biomarker-guided patient selection may be required to demonstrate a beneficial effect of TPE in long COVID.
- Open Access
- 25 July 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04214
Therapeutic plasma exchange in critically ill patients in low-income and lower-middle-income countries: medical need and feasibility
Therapeutic plasma exchange (TPE) is a blood purification technique designed for the removal of large molecules such as pathogenic antibodies and lipoproteins. The procedure involves removing plasma from the patient in exchange for replacement fluid, and it can be performed either by membrane separation or centrifugation. These conventional techniques are expensive and require the training of skilled personnel. This severely limits their use in low-income countries (LICs) and lower-middle-income countries (LMICs), leading to morbidity and mortality for patients in LICs and LMICs suffering from the diseases where TPE is indicated. A novel gravity-driven blood separation method might provide the needed access to TPE for LICs and LMICs. We reviewed the medical need, the practical aspects, as well as the possible complications of applying this novel technology in LICs and LMICs. Furthermore, we describe a feasibility study of implementing TPE in Suriname for various diseases and conditions. Where data was available (n /N = 10/11), supportive care combined with TPE using the new device resulted in improved values for the disease-specific markers evaluated in these patients. In addition, eight patients showed complete clinical recovery, and one patient showed partial clinical recovery upon TPE within 0.5-6 months of follow-up. Importantly, none of the patients experienced any serious side effects. This experience in the resource-limited setting in Suriname illustrates that its application is feasible in LICs and LMICs settings, at least for these five diseases with first-line indications for TPE and a significant number of patients.
- 25 July 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04214
Open AccessTherapeutic plasma exchange in critically ill patients in low-income and lower-middle-income countries: medical need and feasibility
Therapeutic plasma exchange (TPE) is a blood purification technique designed for the removal of large molecules such as pathogenic antibodies and lipoproteins. The procedure involves removing plasma from the patient in exchange for replacement fluid, and it can be performed either by membrane separation or centrifugation. These conventional techniques are expensive and require the training of skilled personnel. This severely limits their use in low-income countries (LICs) and lower-middle-income countries (LMICs), leading to morbidity and mortality for patients in LICs and LMICs suffering from the diseases where TPE is indicated. A novel gravity-driven blood separation method might provide the needed access to TPE for LICs and LMICs. We reviewed the medical need, the practical aspects, as well as the possible complications of applying this novel technology in LICs and LMICs. Furthermore, we describe a feasibility study of implementing TPE in Suriname for various diseases and conditions. Where data was available (n /N = 10/11), supportive care combined with TPE using the new device resulted in improved values for the disease-specific markers evaluated in these patients. In addition, eight patients showed complete clinical recovery, and one patient showed partial clinical recovery upon TPE within 0.5-6 months of follow-up. Importantly, none of the patients experienced any serious side effects. This experience in the resource-limited setting in Suriname illustrates that its application is feasible in LICs and LMICs settings, at least for these five diseases with first-line indications for TPE and a significant number of patients.
- Open Access
- 25 June 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 172 (1) , 396-405
Feasibility and effectiveness of the novel HemoClear microfiltration cell‐salvage system in cesarean sections in South Africa
Objective: To test the feasibility and effectiveness of implementing the HemoClear microfiltration cell‐salvage system for cesarean sections in South Africa. Methods: We conducted a prospective experimental single‐arm feasibility study collecting and processing blood from 20 adult women undergoing cesarean section in Pelonomi Tertiary Hospital, Bloemfontein. Samples obtained from the blood salvaged during the cesarean section before (baseline) and after (concentrate and filtrate) the cell‐salvage procedure were tested for cellular, protein, electrolyte, and metabolic parameters, as well as blood coagulation and bacterial or amniotic fluid contamination. Results: Median erythrocyte recovery using the HemoClear device was 75.5% (interquartile range [IQR], 63.8%–94.3%). An average volume of 826 ± 146 mL was processed in 15.3 ± 6.3 min, resulting in 266 ± 116 mL of cell concentrate. The filtration procedure washed away >75% of the α‐fetoprotein content in the concentrate, resulting in a median recovery of 24.0% (IQR, 21.4%–35.9%). Bacterial contamination was mostly consistent between baseline and concentrate for each patient and resulted mainly from normal skin flora. In six patients, nonskin species were detected. Conclusion: This study shows the HemoClear system's adaptability to resource‐constrained environments, which opens the door for broader adoption of its use in similar resource‐constrained settings. The HemoClear cell‐salvage device is safe and efficient for intraoperative use in obstetric hemorrhage cases and can play an essential role in patient blood management.
- 25 June 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 172 (1) , 396-405
Open AccessFeasibility and effectiveness of the novel HemoClear microfiltration cell‐salvage system in cesarean sections in South Africa
Objective: To test the feasibility and effectiveness of implementing the HemoClear microfiltration cell‐salvage system for cesarean sections in South Africa. Methods: We conducted a prospective experimental single‐arm feasibility study collecting and processing blood from 20 adult women undergoing cesarean section in Pelonomi Tertiary Hospital, Bloemfontein. Samples obtained from the blood salvaged during the cesarean section before (baseline) and after (concentrate and filtrate) the cell‐salvage procedure were tested for cellular, protein, electrolyte, and metabolic parameters, as well as blood coagulation and bacterial or amniotic fluid contamination. Results: Median erythrocyte recovery using the HemoClear device was 75.5% (interquartile range [IQR], 63.8%–94.3%). An average volume of 826 ± 146 mL was processed in 15.3 ± 6.3 min, resulting in 266 ± 116 mL of cell concentrate. The filtration procedure washed away >75% of the α‐fetoprotein content in the concentrate, resulting in a median recovery of 24.0% (IQR, 21.4%–35.9%). Bacterial contamination was mostly consistent between baseline and concentrate for each patient and resulted mainly from normal skin flora. In six patients, nonskin species were detected. Conclusion: This study shows the HemoClear system's adaptability to resource‐constrained environments, which opens the door for broader adoption of its use in similar resource‐constrained settings. The HemoClear cell‐salvage device is safe and efficient for intraoperative use in obstetric hemorrhage cases and can play an essential role in patient blood management.
- Open Access
- 25 April 2023
- Published by American Society for Microbiology in mBio
- Vol. 14 (2) , e0337922
Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname
This study compares mortality and other endpoints between intensive care unit COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low- and middle-income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR, 0.35; 95% CI, 0.19 to 0.66; P = 0.001).
- 25 April 2023
- Published by American Society for Microbiology in mBio
- Vol. 14 (2) , e0337922
Open AccessReduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname
This study compares mortality and other endpoints between intensive care unit COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low- and middle-income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR, 0.35; 95% CI, 0.19 to 0.66; P = 0.001).
- Open Access
Reduced mortality among COVID-19 ICU patients after treatment with HemoClear convalescent plasma in Suriname
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but its efficacy in intensive care unit (ICU) patients in a low and middle income country setting such as Suriname is unknown. Bedside plasma separation using the HemoClear device made convalescent plasma therapy accessible as treatment option in Suriname. Two hundred patients with severe SARS-CoV-2 infection requiring intensive care were recruited. Fifty eight patients (29%) received COVID-19 convalescent plasma (CCP) treatment in addition to standard of care (SOC). The CCP treatment and SOC groups were matched by age, sex, and disease severity scores. Mortality in the CCP treatment group was significantly lower than in the SOC group (21% versus 39%; Fisher’s exact P = 0.0133). Multivariate analysis using ICU days showed that CCP treatment reduced mortality (hazard ratio [HR], 0.35; 95% CI, 0.18–0.66; P = 0.001), while complication of acute renal failure (creatinine levels >110 mol/L; HR, 4.45; 95%CI, 2.54-7.80; P < 0.0001) was independently associated with death. Decrease in chest X-ray score in the CCP treatment group (median -3 points, IQR -4 to -1) was significantly greater than in the SOC group (median -1 point, IQR -3 to 1, Mann Whitney P = 0.0004). Improvement in PaO2/FiOs ratio was also significantly greater in the CCP treatment group (median 83, IQR 8 to 140) than in the SOC group (median 35, IQR -3 to 92, Mann Whitney P = 0.0234). Further research is needed for HemoClear-produced CCP as therapy in SARS-CoV-2 infections together with adequately powered, randomized controlled trials. Importance: This study compares mortality and other endpoints between intensive care unit (ICU) COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low and middle income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR 0.35; 95% CI, 0.19–0.66; P = 0.001). Although this is an exploratory study, it clearly shows the benefit of using the HemoClear-produced CCP in ICU patients in the Suriname LMIC setting. Additional studies can further substantiate our findings and their applicability to both LMICs and high income countries and the use of CCP as a prepared readiness method to combat new viral pandemics.
Open AccessReduced mortality among COVID-19 ICU patients after treatment with HemoClear convalescent plasma in Suriname
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but its efficacy in intensive care unit (ICU) patients in a low and middle income country setting such as Suriname is unknown. Bedside plasma separation using the HemoClear device made convalescent plasma therapy accessible as treatment option in Suriname. Two hundred patients with severe SARS-CoV-2 infection requiring intensive care were recruited. Fifty eight patients (29%) received COVID-19 convalescent plasma (CCP) treatment in addition to standard of care (SOC). The CCP treatment and SOC groups were matched by age, sex, and disease severity scores. Mortality in the CCP treatment group was significantly lower than in the SOC group (21% versus 39%; Fisher’s exact P = 0.0133). Multivariate analysis using ICU days showed that CCP treatment reduced mortality (hazard ratio [HR], 0.35; 95% CI, 0.18–0.66; P = 0.001), while complication of acute renal failure (creatinine levels >110 mol/L; HR, 4.45; 95%CI, 2.54-7.80; P < 0.0001) was independently associated with death. Decrease in chest X-ray score in the CCP treatment group (median -3 points, IQR -4 to -1) was significantly greater than in the SOC group (median -1 point, IQR -3 to 1, Mann Whitney P = 0.0004). Improvement in PaO2/FiOs ratio was also significantly greater in the CCP treatment group (median 83, IQR 8 to 140) than in the SOC group (median 35, IQR -3 to 92, Mann Whitney P = 0.0234). Further research is needed for HemoClear-produced CCP as therapy in SARS-CoV-2 infections together with adequately powered, randomized controlled trials. Importance: This study compares mortality and other endpoints between intensive care unit (ICU) COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low and middle income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR 0.35; 95% CI, 0.19–0.66; P = 0.001). Although this is an exploratory study, it clearly shows the benefit of using the HemoClear-produced CCP in ICU patients in the Suriname LMIC setting. Additional studies can further substantiate our findings and their applicability to both LMICs and high income countries and the use of CCP as a prepared readiness method to combat new viral pandemics.
- Open Access
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
Objective: Macrophage interleukin (IL)-10 signalling plays a critical role in the maintenance of a regulatory phenotype that prevents the development of IBD. We have previously found that anti-tumour necrosis factor (TNF) monoclonal antibodies act through Fcγ-receptor (FcγR) signalling to promote repolarisation of proinflammatory intestinal macrophages to a CD206+ regulatory phenotype. The role of IL-10 in anti-TNF-induced macrophage repolarisation has not been examined. Design: We used human peripheral blood monocytes and mouse bone marrow-derived macrophages to study IL-10 production and CD206+ regulatory macrophage differentiation. To determine whether the efficacy of anti-TNF was dependent on IL-10 signalling in vivo and in which cell type, we used the CD4+CD45Rb high T-cell transfer model in combination with several genetic mouse models. Results: Anti-TNF therapy increased macrophage IL-10 production in an FcγR-dependent manner, which caused differentiation of macrophages to a more regulatory CD206+ phenotype in vitro. Pharmacological blockade of IL-10 signalling prevented the induction of these CD206+ regulatory macrophages and diminished the therapeutic efficacy of anti-TNF therapy in the CD4+CD45Rb high T-cell transfer model of IBD. Using cell type-specific IL-10 receptor mutant mice, we found that IL-10 signalling in macrophages but not T cells was critical for the induction of CD206+ regulatory macrophages and therapeutic response to anti-TNF. Conclusion: The therapeutic efficacy of anti-TNF in resolving intestinal inflammation is critically dependent on IL-10 signalling in macrophages.
Open AccessAnti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
Objective: Macrophage interleukin (IL)-10 signalling plays a critical role in the maintenance of a regulatory phenotype that prevents the development of IBD. We have previously found that anti-tumour necrosis factor (TNF) monoclonal antibodies act through Fcγ-receptor (FcγR) signalling to promote repolarisation of proinflammatory intestinal macrophages to a CD206+ regulatory phenotype. The role of IL-10 in anti-TNF-induced macrophage repolarisation has not been examined. Design: We used human peripheral blood monocytes and mouse bone marrow-derived macrophages to study IL-10 production and CD206+ regulatory macrophage differentiation. To determine whether the efficacy of anti-TNF was dependent on IL-10 signalling in vivo and in which cell type, we used the CD4+CD45Rb high T-cell transfer model in combination with several genetic mouse models. Results: Anti-TNF therapy increased macrophage IL-10 production in an FcγR-dependent manner, which caused differentiation of macrophages to a more regulatory CD206+ phenotype in vitro. Pharmacological blockade of IL-10 signalling prevented the induction of these CD206+ regulatory macrophages and diminished the therapeutic efficacy of anti-TNF therapy in the CD4+CD45Rb high T-cell transfer model of IBD. Using cell type-specific IL-10 receptor mutant mice, we found that IL-10 signalling in macrophages but not T cells was critical for the induction of CD206+ regulatory macrophages and therapeutic response to anti-TNF. Conclusion: The therapeutic efficacy of anti-TNF in resolving intestinal inflammation is critically dependent on IL-10 signalling in macrophages.
- Open Access
- 8 May 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Transient opening of trimeric prefusion RSV F proteins
The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion protein that mediates viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of RSV F, as well as other class I fusion proteins, have revealed compact trimeric arrangements, yet whether these trimeric forms can transiently open remains unknown. Here, we perform structural and biochemical studies on a recently isolated antibody, CR9501, and demonstrate that it enhances the opening of prefusion-stabilized RSV F trimers. The 3.3 Å crystal structure of monomeric RSV F bound to CR9501, combined with analysis of over 25 previously determined RSV F structures, reveals a breathing motion of the prefusion conformation. We also demonstrate that full-length RSV F trimers transiently open and dissociate on the cell surface. Collectively, these findings have implications for the function of class I fusion proteins, as well as antibody prophylaxis and vaccine development for RSV.
- 8 May 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Open AccessTransient opening of trimeric prefusion RSV F proteins
The respiratory syncytial virus (RSV) F glycoprotein is a class I fusion protein that mediates viral entry and is a major target of neutralizing antibodies. Structures of prefusion forms of RSV F, as well as other class I fusion proteins, have revealed compact trimeric arrangements, yet whether these trimeric forms can transiently open remains unknown. Here, we perform structural and biochemical studies on a recently isolated antibody, CR9501, and demonstrate that it enhances the opening of prefusion-stabilized RSV F trimers. The 3.3 Å crystal structure of monomeric RSV F bound to CR9501, combined with analysis of over 25 previously determined RSV F structures, reveals a breathing motion of the prefusion conformation. We also demonstrate that full-length RSV F trimers transiently open and dissociate on the cell surface. Collectively, these findings have implications for the function of class I fusion proteins, as well as antibody prophylaxis and vaccine development for RSV.
- Open Access
- 25 July 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity
The early-life intestinal microbiota plays a key role in shaping host immune system development. We found that a single early-life antibiotic course (1PAT) accelerated type 1 diabetes (T1D) development in male NOD mice. The single course had deep and persistent effects on the intestinal microbiome, leading to altered cecal, hepatic, and serum metabolites. The exposure elicited sex-specific effects on chromatin states in the ileum and liver and perturbed ileal gene expression, altering normal maturational patterns. The global signature changes included specific genes controlling both innate and adaptive immunity. Microbiome analysis revealed four taxa each that potentially protect against or accelerate T1D onset, that were linked in a network model to specific differences in ileal gene expression. This simplified animal model reveals multiple potential pathways to understand pathogenesis by which early-life gut microbiome perturbations alter a global suite of intestinal responses, contributing to the accelerated and enhanced T1D development.
- 25 July 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Open AccessAntibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunity
The early-life intestinal microbiota plays a key role in shaping host immune system development. We found that a single early-life antibiotic course (1PAT) accelerated type 1 diabetes (T1D) development in male NOD mice. The single course had deep and persistent effects on the intestinal microbiome, leading to altered cecal, hepatic, and serum metabolites. The exposure elicited sex-specific effects on chromatin states in the ileum and liver and perturbed ileal gene expression, altering normal maturational patterns. The global signature changes included specific genes controlling both innate and adaptive immunity. Microbiome analysis revealed four taxa each that potentially protect against or accelerate T1D onset, that were linked in a network model to specific differences in ileal gene expression. This simplified animal model reveals multiple potential pathways to understand pathogenesis by which early-life gut microbiome perturbations alter a global suite of intestinal responses, contributing to the accelerated and enhanced T1D development.
- Open Access
- 28 March 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (7) , 794-803
Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease
Although several endoscopic and histopathologic indices are available for evaluating the severity of inflammation in mouse models of colitis, the reliability of these scoring instruments is unknown. Our aim was to evaluate the reliability of the individual items in the existing indices and develop new scoring systems by selection of the most reliable index items. Two observers scored the histological slides [n = 224] and endoscopy videos [n = 201] from treated and untreated Interleukin[IL]-10 knock-out and T-cell transferred SCID mice. Intra-rater and inter-rater reliability for endoscopy and histology scores, and each individual item, were measured using intraclass correlation coefficients [ICCs]. The Mouse Colitis Histology Index [MCHI] and Mouse Colitis Endoscopy Index [MCEI] were developed using the most reliable items. Both were correlated to the colon density and to each other and were evaluated for their ability to detect changes in pathobiology. The intraclass correlation coefficients (ICCs) for inter-rater agreement (95% CIs) for the total histology and endoscopy scores were 0.90 [0.87–0.92] and 0.80 [0.76–0.84], respectively. The MCHI and MCEI were highly correlated with colon density, with a Spearman Rho = 0.81[0.75–0.85] and 0.73 [0.66–0.79], respectively, and with each other, Spearman Rho = 0.71 [0.63–0.77]. The MCHI and MCEI were able to distinguish between the experimental groups within the models, with pairwise differences between the treated and untreated groups being statistically significant [p < 0.001]. These histological and endoscopic indices are valid and reliable measures of intestinal inflammation in mice, and they are responsive to treatment effects in pre-clinical studies.
- 28 March 2018
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 12 (7) , 794-803
Open AccessDevelopment of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease
Although several endoscopic and histopathologic indices are available for evaluating the severity of inflammation in mouse models of colitis, the reliability of these scoring instruments is unknown. Our aim was to evaluate the reliability of the individual items in the existing indices and develop new scoring systems by selection of the most reliable index items. Two observers scored the histological slides [n = 224] and endoscopy videos [n = 201] from treated and untreated Interleukin[IL]-10 knock-out and T-cell transferred SCID mice. Intra-rater and inter-rater reliability for endoscopy and histology scores, and each individual item, were measured using intraclass correlation coefficients [ICCs]. The Mouse Colitis Histology Index [MCHI] and Mouse Colitis Endoscopy Index [MCEI] were developed using the most reliable items. Both were correlated to the colon density and to each other and were evaluated for their ability to detect changes in pathobiology. The intraclass correlation coefficients (ICCs) for inter-rater agreement (95% CIs) for the total histology and endoscopy scores were 0.90 [0.87–0.92] and 0.80 [0.76–0.84], respectively. The MCHI and MCEI were highly correlated with colon density, with a Spearman Rho = 0.81[0.75–0.85] and 0.73 [0.66–0.79], respectively, and with each other, Spearman Rho = 0.71 [0.63–0.77]. The MCHI and MCEI were able to distinguish between the experimental groups within the models, with pairwise differences between the treated and untreated groups being statistically significant [p < 0.001]. These histological and endoscopic indices are valid and reliable measures of intestinal inflammation in mice, and they are responsive to treatment effects in pre-clinical studies.
- Open Access
- 6 March 2018
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 14 (3) , e1006935
Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants and the elderly, and yet there remains no effective treatment or vaccine. The surface of the virion is decorated with the fusion glycoprotein (RSV F) and the attachment glycoprotein (RSV G), which binds to CX3CR1 on human airway epithelial cells to mediate viral attachment and subsequent infection. RSV G is a major target of the humoral immune response, and antibodies that target the central conserved region of G have been shown to neutralize both subtypes of RSV and to protect against severe RSV disease in animal models. However, the molecular underpinnings for antibody recognition of this region have remained unknown. Therefore, we isolated two human antibodies directed against the central conserved region of RSV G and demonstrated that they neutralize RSV infection of human bronchial epithelial cell cultures in the absence of complement. Moreover, the antibodies protected cotton rats from severe RSV disease. Both antibodies bound with high affinity to a secreted form of RSV G as well as to a peptide corresponding to the unglycosylated central conserved region. High-resolution crystal structures of each antibody in complex with the G peptide revealed two distinct conformational epitopes that require proper folding of the cystine noose located in the C-terminal part of the central conserved region. Comparison of these structures with the structure of fractalkine (CX3CL1) alone or in complex with a viral homolog of CX3CR1 (US28) suggests that RSV G would bind to CX3CR1 in a mode that is distinct from that of fractalkine. Collectively, these results build on recent studies demonstrating the importance of RSV G in antibody-mediated protection from severe RSV disease, and the structural information presented here should guide the development of new vaccines and antibody-based therapies for RSV. Respiratory syncytial virus (RSV) is a common cause of bronchiolitis and pneumonia, and is a leading cause of infant deaths globally due to infectious disease. Despite decades of research, there is still no vaccine or widespread treatment for RSV. In this study, we isolated two antibodies that bind to the central conserved region of the viral attachment glycoprotein, RSV G. The antibodies effectively neutralize both subtypes of RSV and protect RSV-challenged animals from severe disease. We also determined high-resolution crystal structures of each antibody in complex with the central conserved region of RSV G to gain a better understanding of how these antibodies bind to RSV G and how they neutralize the virus. Because RSV G is a small folded domain bounded by unstructured mucin-like domains, structural elucidation of the central conserved region provides atomic-level information for the complete folded portion of RSV G. The results presented here will help develop effective antibodies for passive prophylaxis as well as guide efforts to design vaccines that elicit broadly neutralizing antibodies against RSV G.
- 6 March 2018
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 14 (3) , e1006935
Open AccessStructural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants and the elderly, and yet there remains no effective treatment or vaccine. The surface of the virion is decorated with the fusion glycoprotein (RSV F) and the attachment glycoprotein (RSV G), which binds to CX3CR1 on human airway epithelial cells to mediate viral attachment and subsequent infection. RSV G is a major target of the humoral immune response, and antibodies that target the central conserved region of G have been shown to neutralize both subtypes of RSV and to protect against severe RSV disease in animal models. However, the molecular underpinnings for antibody recognition of this region have remained unknown. Therefore, we isolated two human antibodies directed against the central conserved region of RSV G and demonstrated that they neutralize RSV infection of human bronchial epithelial cell cultures in the absence of complement. Moreover, the antibodies protected cotton rats from severe RSV disease. Both antibodies bound with high affinity to a secreted form of RSV G as well as to a peptide corresponding to the unglycosylated central conserved region. High-resolution crystal structures of each antibody in complex with the G peptide revealed two distinct conformational epitopes that require proper folding of the cystine noose located in the C-terminal part of the central conserved region. Comparison of these structures with the structure of fractalkine (CX3CL1) alone or in complex with a viral homolog of CX3CR1 (US28) suggests that RSV G would bind to CX3CR1 in a mode that is distinct from that of fractalkine. Collectively, these results build on recent studies demonstrating the importance of RSV G in antibody-mediated protection from severe RSV disease, and the structural information presented here should guide the development of new vaccines and antibody-based therapies for RSV. Respiratory syncytial virus (RSV) is a common cause of bronchiolitis and pneumonia, and is a leading cause of infant deaths globally due to infectious disease. Despite decades of research, there is still no vaccine or widespread treatment for RSV. In this study, we isolated two antibodies that bind to the central conserved region of the viral attachment glycoprotein, RSV G. The antibodies effectively neutralize both subtypes of RSV and protect RSV-challenged animals from severe disease. We also determined high-resolution crystal structures of each antibody in complex with the central conserved region of RSV G to gain a better understanding of how these antibodies bind to RSV G and how they neutralize the virus. Because RSV G is a small folded domain bounded by unstructured mucin-like domains, structural elucidation of the central conserved region provides atomic-level information for the complete folded portion of RSV G. The results presented here will help develop effective antibodies for passive prophylaxis as well as guide efforts to design vaccines that elicit broadly neutralizing antibodies against RSV G.